Literature DB >> 10661874

Vascular endothelial growth factor (VEGF) and its receptors in tumor-bearing dogs.

P Scheidegger1, W Weiglhofer, S Suarez, B Kaser-Hotz, R Steiner, K Ballmer-Hofer, R Jaussi.   

Abstract

The molecular biology of the angiogenic growth factor, vascular endothelial growth factor (VEGF), has been studied in the dog. All major isoforms of VEGF are present in the dog. The amino acid sequences are identical between human and dog in the loop regions that are responsible for receptor binding. Accordingly, the VEGF receptors of dogs and humans are very similar and permit functional exchange of the growth factor. Here we show that canine VEGF activates human endothelial cells to the same extent as human VEGF. Similarly, the two proteins display identical cell binding properties. The VEGF receptor 1 (Flt-1) shows the same alternative splicing in humans and dogs and is overexpressed in the majority of tumors in both species. VEGF occurs also in canine tumors in similar relative quantities as in human malignancies. Based on the literature and our study we suggest that the molecular biology and the function of the VEGF signaling system are virtually identical in humans and canines and in healthy as well as in disease conditions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10661874     DOI: 10.1515/BC.1999.187

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  7 in total

1.  Signalling properties of an HIV-encoded angiogenic peptide mimicking vascular endothelial growth factor activity.

Authors:  P Scheidegger; W Weiglhofer; S Suarez; S Console; J Waltenberger; M S Pepper; R Jaussi; K Ballmer-Hofer
Journal:  Biochem J       Date:  2001-02-01       Impact factor: 3.857

2.  Increased expression of vascular endothelial growth factor in neo-vascularized canine brain tissue.

Authors:  Chi-Ho Yu; Ji-Young Yhee; Jong-Hyuk Kim; Keum-Soon Im; Na-Hyun Kim; So-Young Kwon; Tai-Young Hur; Jung-Hyang Sur
Journal:  Can J Vet Res       Date:  2012-01       Impact factor: 1.310

3.  Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK and endothelial cell organization.

Authors:  Harukiyo Kawamura; Xiujuan Li; Katsutoshi Goishi; Laurens A van Meeteren; Lars Jakobsson; Stéphanie Cébe-Suarez; Akio Shimizu; Dan Edholm; Kurt Ballmer-Hofer; Lena Kjellén; Michael Klagsbrun; Lena Claesson-Welsh
Journal:  Blood       Date:  2008-07-29       Impact factor: 22.113

4.  Phage-derived fully human monoclonal antibody fragments to human vascular endothelial growth factor-C block its interaction with VEGF receptor-2 and 3.

Authors:  Matthias Rinderknecht; Alessandra Villa; Kurt Ballmer-Hofer; Dario Neri; Michael Detmar
Journal:  PLoS One       Date:  2010-08-02       Impact factor: 3.240

5.  Serum vascular endothelial growth factor in dogs with various proliferative diseases.

Authors:  Hiro Horikirizono; Kumiko Ishigaki; Keigo Iizuka; Kei Tamura; Naoki Sakurai; Kazuyuki Terai; Tatsuya Heishima; Orie Yoshida; Kazushi Asano
Journal:  J Vet Med Sci       Date:  2022-04-04       Impact factor: 1.105

6.  Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach.

Authors:  S M Zeisberger; B Odermatt; C Marty; A H M Zehnder-Fjällman; K Ballmer-Hofer; R A Schwendener
Journal:  Br J Cancer       Date:  2006-07-11       Impact factor: 7.640

7.  VEGFR-2 conformational switch in response to ligand binding.

Authors:  Sarvenaz Sarabipour; Kurt Ballmer-Hofer; Kalina Hristova
Journal:  Elife       Date:  2016-04-07       Impact factor: 8.140

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.